Annals of hepatology 2 , 6975 (2003)
FoxAI is built on higher-resolution clinical trial data and real-world evidence that personalizes the answer rather than reciting the FDA-trial headlines
Composition GHK-Cu: 50 mg KPV: 10 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, KPV tripeptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of four co-formulated peptides Stability characterization of a four-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
1 2 3 4 5 "Glutathione transferases: a structural perspective"
Comparing BPC-157 with Other Treatments BPC-157 offers several advantages over traditional joint pain treatments: Faster Recovery: Unlike conventional methods, BPC-157 can accelerate the healing process
